Daily Cosmetic Research Analysis
Analyzed 3 papers and selected 3 impactful papers.
Summary
Analyzed 3 papers and selected 3 impactful articles.
Selected Articles
1. The effects of cetylpyridinium chloride mouthwash combined with triamcinolone acetonide on oral microbiota and the Th17/Treg balance in patients with oral lichen planus.
In a 80‑patient controlled study of erosive oral lichen planus, adding cetylpyridinium chloride mouthwash to topical triamcinolone for 4 weeks significantly improved clinical response rate (95% vs 80%), pain, mucosal healing and erosive area. The combination decreased detection of Staphylococcus and Candida, reduced serum chemerin, Th17 cells, Th17/Treg ratio, IL‑17 and TNF‑α, and increased Treg cells and IL‑10, with similar mild adverse events.
Impact: Provides clinical and immunological evidence that antiseptic mouthwash plus topical steroid improves outcomes and shifts immune balance in OLP, linking microbiome modulation to clinical benefit.
Clinical Implications: Suggests a simple adjunct (CPC mouthwash) to topical steroid therapy for erosive OLP that may accelerate healing, reduce symptoms and modulate pathogenic oral microbes and pro‑inflammatory Th17 responses; could be adopted as an adjunctive treatment pending confirmatory randomized trials.
Key Findings
- Combination therapy produced higher total effective rate (95% vs 80%, P=0.022).
- Significant improvements in VAS pain, mucosal repair, and decrease in erosive area (P values 0.024, 0.002, 0.021 respectively).
- Reduced oral detection rates of Staphylococcus and Candida albicans (P<0.05).
- Immunological shifts: decreased chemerin, Th17 cells, Th17/Treg ratio, IL‑17 and TNF‑α; increased Treg cells and IL‑10 (P values significant).
- No significant increase in adverse reactions; recurrence rates within 3 months lower but not statistically significant.
Methodological Strengths
- Controlled comparative design with a clinically meaningful composite of endpoints (clinical, microbiological, immunological).
- Objective immunologic (Th17/Treg, cytokines) and microbiological measures complement clinical outcomes.
Limitations
- No statement of randomization or blinding; potential allocation bias.
- Moderate sample size (N=80) and short primary follow‑up (4 weeks) limit long‑term efficacy conclusions.
Future Directions: Confirmatory randomized, blinded trials with larger samples and longer follow‑up, mechanistic microbiome sequencing (16S/metagenomics) and dose/frequency optimization of CPC mouthwash.
BACKGROUND: Oral lichen planus (OLP) is a chronic inflammatory disease associated with oral microbiome imbalance and immune dysregulation.
OBJECTIVES: To evaluate the effects of CPC mouthwash combined with triamcinolone acetonide on oral microbiota and Th17/Treg balance in erosive OLP patients.
METHODS: This study involved 80 patients with erosive OLP from January 2023 to January 2025. They were divided into: A control group treated with triamcinolone acetonide and a combination group treated with triamcinolone acetonide plus cetylpyridinium chloride mouthwash. After 4 weeks, primary outcomes included clinical efficacy, visual analog scale (VAS) pain scores, changes in signs and erosive area, oral salivary bacteria detection rate, Th17/Treg ratio, serum adipokine chemerin and cytokine levels (IL-17, TNF-α, IL-10) and OHIP-14 scores. Secondary outcomes were adverse reaction incidence and recurrence rates during follow-up.
RESULTS: The combination group showed better outcomes after 4 weeks of treatment. The total effective rate was 95%, higher than the control group's 80% (P=0.022). The combination group had superior pain relief (P=0.024), better mucosal repair (P=0.002) and a significant decrease in erosive area (P=0.021). It also had lower oral detection rates of Staphylococcus and Candida albicans (P<0.05). Immunologically, the combination therapy significantly reduced serum levels of chemerin, Th17 cells, Th17/Treg ratio, IL-17 and TNF-α (P<0.001), while increasing Treg cells and IL-10 levels (P=0.003), indicating stronger anti-inflammatory and immune-balancing effects. The combination group showed a greater reduction in the OHIP-14 score (P < 0.001), indicating improved oral health-related quality of life. No significant difference in adverse reactions was observed (P>0.05) and all were mild. The combination group had a lower recurrence rate within 3 months post-treatment, although the difference was not statistically significant (P=0.521).
CONCLUSION: The combination of cetylpyridinium chloride mouthwash with triamcinolone acetonide effectively regulates the oral microbiota structure and restores the Th17/Treg immune balance in OLP patients.
2. Demonstrating Clinical Performance of the Elecsys Anti-SARS-CoV-2 Anti-Nucleocapsid Immunoassay Using Real-World Data to Support Regulatory Decision-Making in the USA.
Retrospective review of 567 patients (585 tests) with PCR‑confirmed symptomatic, unvaccinated SARS‑CoV‑2 infection showed that the Elecsys anti‑N immunoassay had a positive percent agreement (PPA) of 96.49% (95% CI 93.66–98.08) in non‑immunocompromised individuals sampled ≥15 days post symptom onset, exceeding the prespecified 90% threshold and consistent across subgroups.
Impact: Validates an anti‑N serologic assay using real‑world clinical data to support regulatory decision‑making, showing high concordance with prior infection in routine practice.
Clinical Implications: Supports the use of Elecsys anti‑N assay for post‑infection serosurveillance and regulatory submissions; reinforces reliability of anti‑N testing ≥15 days after symptom onset in non‑immunocompromised patients.
Key Findings
- Evaluated 585 serologic tests from 567 symptomatic, unvaccinated PCR‑confirmed patients.
- In non‑immunocompromised patients sampled ≥15 DPSO (N=285), PPA = 96.49% (95% CI 93.66–98.08), exceeding prespecified 90% threshold.
- PPA consistent across demographic subgroups, supporting generalizability.
Methodological Strengths
- Large real‑world dataset from electronic medical records and laboratory information systems covering a full pandemic year.
- Predefined primary endpoint and acceptance threshold (≥90%) for regulatory relevance; avoidance of repeated measures per DPSO category.
Limitations
- Retrospective design with potential for selection and information bias.
- Study population limited to a single tertiary medical center and to symptomatic, unvaccinated patients early in the pandemic; results may not generalize to vaccinated or asymptomatic cohorts.
Future Directions: Prospective multi‑center RWD analyses including vaccinated and asymptomatic populations, comparison with other serologic platforms, and assessment of anti‑N performance over longer post‑infection intervals.
INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global public health concern. Anti-nucleocapsid (anti-N) serology is a key tool for identifying prior infection and supporting population-level surveillance. This study evaluated the clinical performance of the Elecsys
METHODS: We conducted a retrospective review of electronic medical records and laboratory information system data from patients who presented to Columbia University Irving Medical Center from March 2020 to March 2021. Eligible participants were symptomatic, unvaccinated individuals with PCR-confirmed SARS-CoV-2 infection who subsequently underwent serologic testing. Serologic results were categorized by days post symptom onset (DPSO): 0-7, 8-14, and ≥ 15 days. To avoid repeated measures, only the first serologic result per patient within each DPSO category was included. The primary endpoint was positive percent agreement (PPA) for nonimmunocompromised individuals tested at ≥ 15 DPSO, with a prespecified acceptance threshold of ≥ 90%.
RESULTS: A total of 585 serologic tests from 567 patients (77, 45, and 463 samples, in DPSO categories of 0-7, 8-14, and ≥ 15 days, respectively) were evaluated. Among nonimmunocompromised individuals with samples collected ≥ 15 DPSO (N = 285), the PPA was 96.49% (95% confidence interval 93.66%, 98.08%), fulfilling the predefined acceptance criterion. PPA was also consistent across demographic subgroups, supporting the generalizability of the findings.
CONCLUSIONS: This study demonstrates the feasibility of generating robust clinical evidence for regulatory purposes using real-world data. The clinical performance of the Elecsys Anti-SARS-CoV-2 immunoassay was confirmed using data collected under routine conditions during the pandemic, complementing data from controlled clinical studies and contributing to informed regulatory decision-making.
3. Spectrophotometric evaluation of sun protection and antioxidant potential of Artemisia maritima L. and Sophora mollis Royle from Hunza, Gilgit-Baltistan.
In vitro spectrophotometric analyses showed Artemisia maritima extract had higher estimated SPF (17.27 ± 0.31), greater total phenolic and flavonoid contents, and stronger antioxidant activity (DPPH/ABTS) than Sophora mollis. Trolox had the strongest antioxidant activity overall, but A. maritima demonstrated promising photoprotective and free‑radical scavenging properties for potential natural sunscreen formulations.
Impact: Identifies a local plant extract (A. maritima) with measurable SPF and antioxidant properties that could be developed as a natural photoprotective cosmetic ingredient.
Clinical Implications: Currently exploratory — suggests candidate natural photoprotective agents for formulation research, but requires in vivo photoprotection testing, safety/toxicity assessment, and stability/formulation studies before clinical or consumer use.
Key Findings
- A. maritima SPF = 17.27 ± 0.31 vs S. mollis SPF = 7.68 ± 0.18 (spectrophotometric estimation).
- A. maritima had higher total phenolic content (345.93 mg GAE/g) and total flavonoid content (239.30 mg QE/g) than S. mollis.
- Antioxidant IC50 (DPPH): Trolox 50.45 µg/mL, A. maritima 119.52 µg/mL, S. mollis 244.46 µg/mL; ABTS inhibition: 68.3% (A. maritima) vs 60.2% (S. mollis).
Methodological Strengths
- Standardized in vitro assays (UV‑Vis SPF estimation, DPPH and ABTS antioxidant assays, TPC/TFC quantification).
- Quantitative reporting with replicates and concentration metrics allowing direct comparison between species and with Trolox standard.
Limitations
- In vitro spectrophotometric SPF estimation does not substitute for in vivo sun protection efficacy testing (ISO/COLIPA methods).
- No toxicity, irritation, photostability, or formulation data; extraction method and batch variability may influence results.
Future Directions: Proceed to in vivo SPF testing (human/ISO methods), safety/toxicity evaluation, active compound isolation/characterization, photostability and formulation studies to support cosmetic/dermatological use.
BACKGROUND: Excessive ultraviolet (UV) radiation in mountainous regions increases the risk of skin disorders, highlighting the need for effective natural photoprotective agents.
OBJECTIVES: This study aims to evaluate the sun protection factor (SPF) and antioxidant potential of two underexplored plants, Artemisia maritima and Sophora mollis, collected from high-altitude areas of Gilgit-Baltistan, to assess their suitability as natural photoprotective agents.
METHODS: UV-Vis spectroscopy was used to assess free radical scavenging activity (DPPH and ABTS assays), along with total phenolic content (TPC) and total flavonoid content (TFC).
RESULTS: A. maritima exhibited a higher SPF value (17.27 ± 0.31) compared to S. mollis (7.68 ± 0.18). Similarly, A. maritima showed greater TPC (345.93 ± 0.62 mg GAE/g) and TFC (239.30 ± 0.47 mg QE/g) than S. mollis (297.38 ± 0.34 mg GAE/g and 55.26 ± 0.75 mg QE/g, respectively). Antioxidant activity, measured by IC50 values, was strongest for Trolox (50.45 ± 0.97 µg/mL), followed by A. maritima (119.52 ± 2.23 µg/mL) and S. mollis (244.46 ± 8.06 µg/mL). In ABTS assays, A. maritima and S. mollis inhibited 68.3% and 60.2% of free radicals, respectively.
CONCLUSION: These findings suggest that A. maritima possesses strong photoprotective and antioxidant properties, highlighting its potential as a promising natural sunscreen candidate, while S. mollis may provide moderate photoprotection suitable for complementary cosmetic or dermatological formulations.